News
2010-06-16
Biovator's In-Vitro testing alternative on display at ICCA-LRI & JRC workshop...
To view the poster from the workshop click here.
2010-05-17
Biovator AB launches new home page. Latest news about Biovator and the project progresses will be continuously updated.
2009-12-18
Biovator and BASF sign technology development agreement...
2009-08-10
Tove Eriksson, PhD in Clinical Immunology joins Biovator as a Research Scientist. The position of Dr T Eriksson includes project management of R&D activities performed at AstraZeneca.
2008-03-06
Biovator attracts new investment partner...
2007-09-06
Biovator and AstraZeneca join forces to launch a new alternative to animal testing...
2007-03-20
The official start of the EUREKA project "CPA DEVELOPMENT”. The “CPA DEVELOPMENT” has been awarded grants from VINNOVA.
2007-01-29
The Biovator project “CPA DEVELOPMENT” obtained EUREKA status (E! 3964). Biovator AB is the coordinator of a research & development consortium including Medicago AB (Uppsala, Sweden), Linköping University (Linköping, Sweden) and IBL- Hamburg (Hamburg, Germany). The project “CPA DEVELOPMENT” aims at further development of the Cytokine Profile Assay (CPA) - an in vitro assay for the risk assessment of potential sensitizing compounds. Additional information about the project and EUREKA can be found on the EUREKA homepage ( www.eureka.be ).
